Factors Contributing to the Preference of Korean Patients with Crohn's Disease When Selecting an Anti-Tumor Necrosis Factor Agent (CHOICE Study)
- Abstract
- BACKGROUND/AIMS: Two comparable anti-tumor necrosis factor (TNF) agents with different routes of administration (intravenous [iv] infliximab [IFX] vs subcutaneous [sc] adalimumab [ADA]) are available for patients with Crohn's disease (CD) in Korea. This study aimed to identify the preferences of Korean CD patients for a specific anti-TNF agent and the factors contributing to the decision. METHODS: A prospective survey was performed among anti-TNF-naive CD patients in 10 tertiary referral hospitals. A 16-item questionnaire addressed patient preferences and the factors contributing to the decision in favor of a particular anti-TNF agent. A logistic regression was conducted to assess predictive factors for ADA preference. RESULTS: Overall, 189 patients (139 males; mean age, 32.47±11.71 years) completed the questionnaire. IFX and ADA were preferred by 63.5% (120/189) and 36.5% (69/189) of patients, respectively. The most influential reason for choosing IFX was 'doctor's presence' (68.3%, 82/120), and ADA was easy to use" (34.8%, 24/69). Amid various clinicodemographic data, having a >60-minute travel time to the hospital was a significant independent predictive factor for ADA preference. CONCLUSIONS: A large number of anti-TNF-naive Korean patients with CD preferred anti-TNFs with an iv route of administration. The reassuring effect of a doctor's presence might be the main contributing factor for this decision."
- All Author(s)
- E. S. Kim
; K. O. Kim
; B. I. Jang
; C. K. Lee
; H. J. Kim
; K. M. Lee
; Y. S. Kim
; C. S. Eun
; S. A. Jung
; S. K. Yang
; J. Lee
; T. O. Kim
; Y. Jung
; G. S. Seo
; S. M. Yoon
- Issued Date
- 2016
- Type
- Article
- Keyword
- Crohn disease; Infliximab; Adalimumab; Preference
- Publisher
- 대한소화기학회
- ISSN
- 1976-2283
- Citation Title
- Gut and Liver
- Citation Volume
- 10
- Citation Number
- 3
- Citation Start Page
- 391
- Citation End Page
- 398
- Language(ISO)
- eng
- DOI
- 10.5009/gnl15126
- URI
- http://schca-ir.schmc.ac.kr/handle/2022.oak/2968
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.